Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRhythm HoldingsFRA:I25 -0.52%79 3-1 Month Momentum % is 6.19% as of Sep. 17, 2026. GuruFocus rates FRA:I25 with a GF Score™ of 79/100 and a GF Value™ of €133.59 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 841 Medical Devices & Instruments companies, iRhythm Holdings ranks better than 81.21% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-17), iRhythm Holdings's 3-1 Month Momentum % is 6.19%.
The industry rank for iRhythm Holdings's 3-1 Month Momentum % or its related term are showing as below:
FRA:I25's 3-1 Month Momentum % is ranked better than 81.21% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs FRA:I25: 6.19
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
iRhythm Holdings 3-1 Month Momentum % Related Terms
FRA:I25 vs ITGR, LIVN, HAE: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, iRhythm Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRhythm Holdings 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Holdings's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where iRhythm Holdings's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iRhythm Holdings (FRA:I25) has a 3-1 Month Momentum % of 6.19% as of Sep. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on iRhythm Holdings and its competitors. According to the industry distribution chart, iRhythm Holdings ranks #158 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 18.8%.
Is iRhythm Holdings' 3-1 Month Momentum % too high?
iRhythm Holdings' current 3-1 Month Momentum % is 6.19%. The Medical Devices & Instruments industry median 3-1 Month Momentum % is 0.95. iRhythm Holdings' value of 6.19% is 551.6% above this industry median. Based on the distribution chart, iRhythm Holdings ranks #158 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, iRhythm Holdings has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRhythm Holdings' 3-1 Month Momentum % compare to ITGR and LIVN?
According to the Medical Devices & Instruments industry distribution chart, iRhythm Holdings ranks #158 out of 841 companies for 3-1 Month Momentum %. This places iRhythm Holdings in the top 19% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 0.95. iRhythm Holdings' value of 6.19% is 551.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
The median 3-1 Month Momentum % among Medical Devices & Instruments companies is 0.95, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRhythm Holdings's current 3-1 Month Momentum % of 6.19% is 551.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on iRhythm Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-1 Month Momentum % is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRhythm Holdings's current 3-1 Month Momentum % is 6.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRhythm Holdings stock overvalued right now?
Based on GuruFocus' analysis, iRhythm Holdings (FRA:I25) is currently considered Modestly Undervalued. The stock's GF Value™ is €133.59, compared to a current price of €95.00 — trading 28.9% below its estimated fair value. The current 3-1 Month Momentum % is 6.19% and 551.6% above the Medical Devices & Instruments industry median of 0.95. iRhythm Holdings' overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For iRhythm Holdings (FRA:I25), the current 3-1 Month Momentum % is 6.19% as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRhythm Holdings (FRA:I25) Overvalued in 2026?
Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued.
The current stock price of €95.00 is trading 28.9% below its estimated GF Value™ of €133.59.
GuruFocus considers iRhythm Holdings to be Modestly Undervalued.
Key valuation signals for FRA:I25:
3-1 Month Momentum %: 6.19%
GF Value™: €133.59 vs. price of €95.00 (28.9% below fair value)
Industry Position: 551.6% above the Medical Devices & Instruments median (#158 of 841)
No single metric tells the full story. See the FRA:I25 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
79GF Score
Get the complete analysis for FRA:I25
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I25 has been successfully added to your 
